Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 5 od 728  
Back povratak na rezultate
2021, vol. 78, br. 6, str. 607-614
Faktori rizika od potencijalnih interakcija između lekova kod bolesnika hospitalizovanih na neurološkom odeljenju
Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Katedra za farmakologiju i toksikologiju

e-adresaradica_zivkovic@yahoo.com
Projekat:
This study was partially supported by bilateral scientific project between Serbia and Montenegro entitled: Risk factors for DDIs in tertiary care hospitals
Farmakološka analiza efekata biološki aktivnih supstanci na izolovane glatke mišiće gastrointestinalnog i urogenitalnog trakta čoveka (MPNTR - 175007)

Ključne reči: nervni sistem, bolesti; lečenje kombinovanjem lekova; lekovi, interakcije; faktori rizika
Sažetak
Uvod/Cilj. Lečenje neuroloških bolesti obično zahteva polifarmaciju, pa je važno otkriti potencijalne interakcije između lekova i prepoznati rizik na vreme jer posledice po bolesnika mogu biti ozbiljne. Cilj ove studije bio je da analizira faktore rizika od pojave, kao i broj potencijalnih interakcija između lekova. Metode. U studiju su bila uključena 144 bolesnika hospitalizovana na Odeljenju opšte neurologije Kliničkog centra Kragujevac. Faktori rizika od interakcija ispitivani su multiplom linearnom regresijom. Studija je imala retrospektivni kohortni dizajn. Frakvencija različitih tipova interakcija bila je prepoznata uz pomoć internet proveravača interakcija (Medscape, Epocrates i Micromedex). Rezultati. Broj propisanih lekova, starost bolesnika, vrednost Charlsonove skale komorbiditeta i propisivanje antidepresiva povećavali su rizik od interakcija na Odeljenju neurologije. Sa druge strane, paralizovanost, broj lekara koji su propisivali lekove po bolesniku, vezanost za postelju na jedan dan hospitalizacije snižavala je verovatnoću za pojavu interakcija između lekova. Broj propisanih lekova po bolesnku [odds ratio (OR) = 1,466 ± 0,250; p = 0,000)] i starost bolesnika (OR = 1,027 ± 0,026; p = 0,041) su povećavali, a broj propisivača po bolesniku (OR = 0,056 ± 0,028; p = 0,016), posebno kod paralizovanih bolesnika (OR = 0,214 ± 0,294; p = 0,007), su smanjili rizik od kontraindikovanih, ozbiljnih, 'koristi alternativu' ili velikih potencijalnih interakcija. Primena antidepresiva povećavala je rizik od nastanka "prati/promeni" interakcija (OR = 1,257 ± 0,726; p = 0.035). Zaključak. Učestalost potencijalnih interakcija između lekova kod neuroloških bolesnika je značajna i povezana je sa godinama života bolesnika, komorbiditetima, brojem propisanih lekova po bolesniku i istovremenom upotrebom antidepresiva.
Reference
Adhiyaman, V., Asghar, M., Oke, A., White, A.D., Shah, I.U. (2001) Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med, 94(10): 512-516
Andersson, M.L., Böttiger, Y., Kockum, H., Eiermann, B. (2018) High Prevalence of Drug-Drug Interactions in Primary Health Care is Caused by Prescriptions from other Healthcare Units. Basic Clin Pharmacol Toxicol, 122(5): 512-518
Aparasu, R., Baer, R., Aparasu, A. (2007) Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm, 3(4): 426-463
Bleakley, S. (2016) Antidepressant drug interactions: Evidence and clinical significance. Progress in Neurology and Psychiatry, 20(3): 21-28
Brodie, M.J., Besag, F., Ettinger, A.B., Mula, M., Gobbi, G., Comai, S., et al. (2016) Antiepileptic Drugs, and Aggression: An Evidence-Based Review. Pharmacol Rev, 68(3): 563-602
Bucsa, C., Moga, D.C., Farcas, A., Mogosan, C., Dumitrascu, D.L. (2015) An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics. Eur Rev Med Pharmacol Sci, 19(15): 2938-2982
Busa, G., Burlina, A., Damuzzo, V., Chiumente, M., Palozzo, A.C. (2018) Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs. J Pharm Pract, 31(1): 58-62
Charlson, M.E., Pompei, P., Ales, K.L., Mackenzie, R.C. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis, 40(5): 373-383
Dagli, R.J., Sharma, A. (2014) Polypharmacy: A global risk factor for elderly people. J Int Oral Health, 6(6): i-ii
Dumbreck, S., Flynn, A., Nairn, M., Wilson, M., Treweek, S., Mercer, S., et al. (2015) Drug-disease and drug-drug interactions: Systematic examination of recommendations in 12 UK national clinical guidelines. BMJ, 350: 949-949
Gidal, B.E., French, J.A., Grossman, P., Le, T.G. (2009) Assessment of potential drug interactions in patients with epilepsy: Impact of age and sex. Neurology, 72(5): 419-25
Guerzoni, S., Pellesi, L., Pini, L.A., Caputo, F. (2018) Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacol Res, 133: 65-76
Kheshti, R., Aalipour, M., Namazi, S. (2016) A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract, 5(4): 257-63
Kim, B.Y., Sharafoddini, A., Tran, N., Wen, E.Y., Lee, J. (2018) Consumer Mobile Apps for Potential Drug-Drug Interaction Check: Systematic Review and Content Analysis Using the Mobile App Rating Scale (MARS). JMIR Mhealth Uhealth, 6(3): 74-74
Lichtner, V., Dowding, D., Esterhuizen, P., Closs, S.J., Long, F.A., Corbett, A., et al. (2014) Pain assessment for people with dementia: A systematic review of systematic reviews of pain assessment tools. BMC Geriatr, 14: 138-138
Lu, Y., Shen, D., Pietsch, M., Nagar, C., Fadli, Z., Huang, H., et al. (2015) A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Sci Rep, 5: 17357-17357
Marengoni, A., Onder, G. (2015) Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ, 350: 1059-1059
Moura, C.S., Acurcio, F.A., Belo, N.O. (2009) Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci, 12(3): 266-72
Namazi, S., Pourhatami, S., Borhani-Haghighi, A., Roosta, S. (2014) Incidence of Potential Drug-Drug Interaction and Related Factors in Hospitalized Neurological Patients in two Iranian Teaching Hospitals. Iran J Med Sci, 39(6): 515-536
Nightingale, G., Pizzi, L.T., Barlow, A., Barlow, B., Jacisin, T., Mcguire, M., et al. (2018) The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. J Geriatr Oncol, 9(5): 526-559
Royal College of Physicians of Ireland National Clinical Programme for Neurology model. Available from: https://www.hse.ie/eng/services/publications/clinicalstrategy-and-programmes/neurology-model-of-care.pdf [accesed 2018 May 24]
Şimşek, A., Taner, N., Macit, Ç., Berk, B., Mercanoğlu, G. (2019) The Importance of Computerized Drug Interaction Checker Programs Used in Community Pharmacies to Avoid Potential Drug Interactions: A Preliminary Study with Clarithromycin. IMJ, 20(1): 67-71
Smithburger, P.L., Kane-Gill, S.L., Seybert, A.L. (2012) Drug-drug interactions in the medical intensive care unit: An assessment of frequency, severity and the medications involved. Int J Pharm Pract, 20(6): 402-408
Teles, J.S., Fukuda, E.Y., Feder, D. (2012) Warfarin: Pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo), 10(1): 110-115
Truven Health Analytics LLC Micromedex® solutions. Available from: https://www.micromedexsolutions.com/home/dispatch/PF DefaultActionId/pf.LoginAction/ssl/true? [accessed date: 10 May2018]
Vingerhoets, R.W., Wieringa, M.H., Egberts, T.C., Jansen, M.M., Jansen, P.A. (2014) Multiple physicians are not independently associated with inappropriate prescribing: A cross-sectional study of geriatric patients. Br J Clin Pharmacol, 77(1): 213-218
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP190401105K
primljen: 01.04.2019.
revidiran: 24.07.2019.
prihvaćen: 30.09.2019.
objavljen onlajn: 01.10.2019.
objavljen u SCIndeksu: 29.06.2021.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

Acta fac medic Naissensis (2019)
Prediktori mogućih interakcija između lekova kod pacijenata u intenzivnoj nezi
Iličković Ivana, i dr.